Oravax H. pylori oral vaccine Phase II study slated for completion in third quarter -- prospectus.

ORAVAX/PASTEUR MERIEUX ORAL H. PYLORI VACCINE PHASE II COMPLETION expected during the third quarter, Oravax reports in the prospectus for a recently completed secondary offering. The UreAB vaccine entered Phase II studies in late September at the University of Maryland and the Centre Hospital Universitaire Vaudois (Lausanne, Switzerland). Cambridge, Mass.-based Oravax is developing the H. pylori vaccine in collaboration with Pasteur Merieux under a 1995 agreement.